TW202309099A - 結合於ｈｅｇ１蛋白質之人源化抗體 - Google Patents

結合於ｈｅｇ１蛋白質之人源化抗體 Download PDF

Info

Publication number
TW202309099A
TW202309099A TW111124572A TW111124572A TW202309099A TW 202309099 A TW202309099 A TW 202309099A TW 111124572 A TW111124572 A TW 111124572A TW 111124572 A TW111124572 A TW 111124572A TW 202309099 A TW202309099 A TW 202309099A
Authority
TW
Taiwan
Prior art keywords
cdata
acid sequence
seq
amino acid
ser
Prior art date
Application number
TW111124572A
Other languages
English (en)
Chinese (zh)
Inventor
辻祥太郎
今井浩三
Original Assignee
地方獨立行政法人神奈川縣立病院機構
國立大學法人東京大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 地方獨立行政法人神奈川縣立病院機構, 國立大學法人東京大學 filed Critical 地方獨立行政法人神奈川縣立病院機構
Publication of TW202309099A publication Critical patent/TW202309099A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
TW111124572A 2021-06-30 2022-06-30 結合於ｈｅｇ１蛋白質之人源化抗體 TW202309099A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-108506 2021-06-30
JP2021108506 2021-06-30

Publications (1)

Publication Number Publication Date
TW202309099A true TW202309099A (zh) 2023-03-01

Family

ID=84691859

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111124572A TW202309099A (zh) 2021-06-30 2022-06-30 結合於ｈｅｇ１蛋白質之人源化抗體

Country Status (4)

Country Link
US (1) US20250092152A1 (https=)
JP (1) JPWO2023277113A1 (https=)
TW (1) TW202309099A (https=)
WO (1) WO2023277113A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813388A (zh) 2023-03-02 2025-10-17 日本医事物理股份有限公司 放射性金属标记抗体、放射性药物及化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699159B (zh) * 2016-02-15 2022-07-29 地方独立行政法人神奈川县立病院机构 膜型粘蛋白样蛋白质的识别及其医疗应用

Also Published As

Publication number Publication date
JPWO2023277113A1 (https=) 2023-01-05
US20250092152A1 (en) 2025-03-20
WO2023277113A1 (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
JP6869218B2 (ja) Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
TWI897855B (zh) Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CN103747803B (zh) 抗axl抗体及其用途
CN105188749B (zh) 抗ntb‑a抗体及相关组合物和方法
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
TWI872044B (zh) 抗ｃｄ２２８抗體及抗體－藥物共軛體
EP2668209B1 (en) Antibodies selective for cells presenting egfr at high density
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
CN104936621A (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
JP2024532598A (ja) 抗Ｎｅｃｔｉｎ－４抗体、抗体薬物複合体、その製造方法及び使用
TWI843105B (zh) 抗her2 抗體藥物偶聯物在治療尿路上皮癌中的用途
IL305954A (en) Nectin-4 protein antibody and extacan compounds
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
WO2024109944A1 (zh) 抗liv-1抗体、其药物偶联物及其医药用途
JP2024020436A (ja) Ｈｅｒ２標的化剤
TW202309099A (zh) 結合於ｈｅｇ１蛋白質之人源化抗體
WO2025086268A1 (en) Cancer treatment with anti-claudin 18.2 adc
WO2023222068A1 (en) Anti-cd200r1 antibodies
WO2018142323A1 (en) Anti-psma antibodies and uses thereof for diagnostic and therapeutic applications
CN120693178A (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途